References

Managing menopausal symptoms and associated clinical issues in breast cancer survivors

10.1210/jc.2017-01138 · 2017 · External reference

The 2022 hormone therapy position statement of The North American Menopause Society

10.1097/gme.0000000000002028 · 2022 · External reference

Use of transdermal testosterone to treat menopausal symptoms in women with a history of breast cancer: a small, retrospective, open-label study

2026 · External reference

Global Consensus Position Statement on the Use of Testosterone Therapy for Women

10.1210/jc.2019-01603 · 2019 · External reference

International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women

10.1016/j.jsxm.2020.10.009 · 2021 · External reference

The 2023 nonhormone therapy position statement of The North American Menopause Society

10.1097/gme.0000000000002200 · 2023 · External reference

Not just sex: other roles for testosterone in women

10.1080/13697137.2024.2445301 · 2025 · External reference

Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT

10.1210/clinem/dgad058 · 2023 · External reference

Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials

10.1001/jama.2024.14618 · 2024 · External reference

Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer

10.1056/nejmoa2415566 · 2025 · External reference

Libigel (testosterone gel) does not differentiate from placebo therapy in the treatment of hypoactive sexual desire in postmenopausal women (Abstract)

2012 · External reference

Testosterone for low libido in postmenopausal women not taking estrogen

10.1056/nejmoa0707302 · 2008 · External reference